Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

(2021) D. Miles et al.   ANNALS OF ONCOLOGY

Prognostic role of pretreatment blood lymphocyte count in patients with solid tumors: a systematic review and meta-analysis

(2020) Jiawen Zhao et al.   Cancer Cell International

Pembrolizumab for Early Triple-Negative Breast Cancer

(2020) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer

(2020) Ami N Shah et al.   Journal for ImmunoTherapy of Cancer

The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade

(2020) Isobel S. Okoye et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The effects of tumor resection and adjuvant therapy on the peripheral blood immune cell profile in patients with colon carcinoma

(2020) Daniëlle Krijgsman et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

(2020) Sergio Serrano-Villar et al.   Lancet HIV

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

(2020) Elizabeth A Mittendorf et al.   LANCET

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

(2020) Javier Cortes et al.   LANCET

Longitudinal analysis of T-cell receptor repertoires reveals persistence of antigen-driven CD4+ and CD8+ T-cell clusters in systemic sclerosis

(2020) N.H. Servaas et al.   JOURNAL OF AUTOIMMUNITY

Characteristics and prognostic significance of profiling the peripheral blood T-cell receptor repertoire in patients with advanced lung cancer

(2019) Yangyang Liu et al.   INTERNATIONAL JOURNAL OF CANCER

Dynamics in HIV-DNA levels over time in HIV controllers

(2019) Véronique Avettand-Fenoel et al.   Journal of the International AIDS Society

Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer

(2019) Livius Penter et al.   OncoImmunology

Model to improve specificity for identification of clinically-relevant expanded T cells in peripheral blood

(2019) Julie Rytlewski et al.   PLoS One

Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC).

(2019) David B. Page et al.   JOURNAL OF CLINICAL ONCOLOGY

Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer

(2019) Lei Wang et al.   NATURE IMMUNOLOGY

Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma

(2019) Akiko Arakawa et al.   Frontiers in Immunology

VDJdb in 2019: database extension, new analysis infrastructure and a T-cell receptor motif compendium

(2019) Dmitry V Bagaev et al.   NUCLEIC ACIDS RESEARCH

TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer

(2019) Jiefei Han et al.   Cancer Immunology Research

Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers

(2019) Hongyi Zhang et al.   CLINICAL CANCER RESEARCH

CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy

(2019) Hiroshi Kagamu et al.   Cancer Immunology Research

Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+ 

(2018) Rachael A. Hughes et al.   AIDS

Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer

(2018) Anosheh Afghahi et al.   CLINICAL CANCER RESEARCH

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

(2018) Thomas Duhen et al.   Nature Communications

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Deciphering Diversity Indices for a Better Understanding of Microbial Communities

(2017) Bo-Ra Kim et al.   JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY

Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis

(2017) Alexandra Snyder et al.   PLOS MEDICINE

The generalized Simpson’s entropy is a measure of biodiversity

(2017) Michael Grabchak et al.   PLoS One

Deep sequencing of blood and gut T-cell receptor β-chains reveals gluten-induced immune signatures in celiac disease

(2017) Dawit A. Yohannes et al.   Scientific Reports

Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes

(2015) Cyrille J. Cohen et al.   JOURNAL OF CLINICAL INVESTIGATION

Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma

(2015) Michael A. Postow et al.   Journal for ImmunoTherapy of Cancer

A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice

(2015) Therese Liechtenstein et al.   Oncotarget

Age-Related Decrease in TCR Repertoire Diversity Measured with Deep and Normalized Sequence Profiling

(2014) O. V. Britanova et al.   JOURNAL OF IMMUNOLOGY

Human lymphocyte repertoires in ageing

(2013) Scott D Boyd et al.   CURRENT OPINION IN IMMUNOLOGY

High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer

(2013) Ryan O Emerson et al.   JOURNAL OF PATHOLOGY

Using synthetic templates to design an unbiased multiplex PCR assay

(2013) Christopher S. Carlson et al.   Nature Communications

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth

(2012) Mélanie Bruchard et al.   NATURE MEDICINE

Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients

(2012) Manuarii Manuel et al.   OncoImmunology

Ultra-sensitive detection of rare T cell clones

(2011) Harlan Robins et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy

(2011) David G. DeNardo et al.   Cancer Discovery

5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity

(2010) J. Vincent et al.   CANCER RESEARCH

Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice

(2010) Lukas W. Pfannenstiel et al.   CELLULAR IMMUNOLOGY

A model for harmonizing flow cytometry in clinical trials

(2010) Holden T Maecker et al.   NATURE IMMUNOLOGY

Comprehensive assessment of T-cell receptor  -chain diversity in    T cells

(2009) H. S. Robins et al.   BLOOD

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses

(2009) W M Liu et al.   BRITISH JOURNAL OF CANCER

Differential requirements of MHC and of DCs for endogenous proliferation of different T-cell subsets in vivo

(2009) J.-s. Do et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA